H.C. Wainwright’s Patrick Trucchio reiterated his Buy rating on Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) and raised his ...

Alnylam Pharmaceuticals Inc. won’t get another chance at its patent infringement suit against Moderna Inc. over its mRNA Covid-19 vaccine, a federal appeals court ruled Wednesday.

Alnylam Pharmaceuticals has put its dancing shoes on to raise awareness of the experience of living with acute hepatic ...

Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new ...

Moderna convinced a U.S. appeals court on Wednesday to uphold a ruling that undercut patent infringement claims by biotech ...

CAMBRIDGE, Mass., May 28, 2025--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Goldman ...

Alnylam Pharmaceuticals has had a lot of excitement this year, with more good news potentially on the way. Summit ...

Buying $1000 In ALNY: If an investor had bought $1000 of ALNY stock 20 years ago, it would be worth $38,973.12 today based on ...

Biogen Inc. is teaming up with a new startup launched by Alnylam Pharmaceuticals’ founding CEO John Maraganore.

Alnylam Pharmaceuticals ALNY has outperformed the market over the past 15 years by 8.93% on an annualized basis producing an average annual return of 20.2%. Currently, Alnylam Pharmaceuticals has ...

Alnylam Pharmaceuticals Inc. Quarterly stock financials by MarketWatch. View the latest ALNY financial statements, income statements and financial ratios. Skip to main content ...